High Flow Nasal Cannula to Prevent Deoxygenation During Induction of General Anesthesia in Cesarean Section

Alexandria University

Status: Unknown

Conditions: Maternal Death; Hypoxic Brain Injury

Treatments: Other: F Group; Other: H Group

Study type: Interventional

Funder types: Other

Identifiers

NCT04438798

0304665

Details and patient eligibility

About

Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) using high flow oxygen therapy for preoxygenation and oxygen supplementation during apnoea has shown promising results

Full description

Eeffective preoxygenation followed by apnoeic oxygenation enables anaesthesiologists to safely prolong the apnoea time which is the time (seconds) of apnea following preoxygenation and muscle relaxation before to peripheral oxygen saturations (SpO2) decreases by 2%.

Enrollment: 80 estimated patients

Sex: Female

Ages: 20 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• pregnant females
• Of American Society of Anesthesiologists (ASA) physical Status I and II
• For elective cesarean section under general anesthesia

Exclusion criteria

• with room air saturation of <98%
• anticipated difficult airway
• anticipated obstetric risk factor or precious baby
• chronic obstructive pulmonary disease
• thyrotoxicosis
• pheochromocytoma
• hyperkalaemia
• significant cardiac illness

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

80 participants in 2 patient groups, including a placebo group

face mask group

Placebo Comparator group

Description:

Pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.

Treatment:

Other: F Group

THRIVE group

Active Comparator group

Description:

High-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.

Treatment:

Other: H Group